RECOMMENDATIONS ON INFLUENZA VACCINATION DURING THE WINTER SEASON

Similar documents
WHO REGIONAL OFFICE FOR EUROPE RECOMMENDATIONS ON INFLUENZA

Summary. Primary care data. Week 49/2014. Season

A report on the epidemiology of selected vaccine-preventable diseases in the European Region 30% 20% 10%

European status report on alcohol and health Leadership, awareness and commitment

Alcohol-related harm in Europe and the WHO policy response

Situation update in the European Region: overview of influenza surveillance data week 40/2009 to week 07/2010.

WHO Meeting on Strengthening measles and rubella laboratory network in the Russian Federation and Newly Independent States

SEASONAL INFLUENZA IN THE WHO EUROPEAN REGION, EARLY SEASON. Situational analysis

European Status report on Alcohol and Health

Highlighting in the WHO European Region: Summary. No. 21(February 2012)

EURO POLIO PAGE Data as of 04 October 2005 (Week 38)

Highlighting in the WHO European Region:

Highlighting in the WHO European Region: measles outbreaks rubella surveillance acute flaccid paralysis surveillance

Media Release. Inaugural study reveals that more than one in four women in European and Central Asian prisons locked up for drug offences

The cancer burden in the European Union and the European Region: the current situation and a way forward

WCPT COUNTRY PROFILE December 2017 SWEDEN

WCPT COUNTRY PROFILE December 2017 HUNGARY

WCPT COUNTRY PROFILE December 2017 SERBIA

Analysis of 3-dose oral/inactivated poliovirus vaccine (OPV3/IPV3) immunization coverage

Q1 What age are you?

Noncommunicable diseases progress monitoring. Are we meeting the time-bound United Nations targets?

Animal health situation of OIE Member Countries in Europe 1 st semester 2012 (and previous)

Acknowledgements. Wild birds and the risk of a pandemic. Overview of the presentation

Where we stand in EFORT

Monitoring noncommunicable disease commitments in Europe Theme in focus: progress monitor indicators

Engagement in language assessment / Regions of Europe

Inequalities in health: challenges and opportunities in Europe Dr Zsuzsanna Jakab WHO Regional Director for Europe

World Health Organization Regional Office for Europe Surveillance of measles and rubella Data as of 15 March 2006

Summary. Week 15/2018 (9 15 April 2018) season overview

Welcome to the new EURO Immunization Monitor

EUDY JUNIOR CAMP 2018 FIRST ANNOUNCEMENT

Summary. Week 13/2018 (26 31 March 2018) season overview

Summary. Week 4/2018 (22 28 January 2018) season overview

Biology Report. Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis?

Public health relevant virological features of Influenza A(H7N9) causing human infection in China

Burden and cost of alcohol, tobacco and illegal drugs globally and in Europe

LEBANON. WCPT COUNTRY PROFILE December 2018

Recommended composition of influenza virus vaccines for use in the 2007 influenza season

DENMARK. WCPT COUNTRY PROFILE December 2018

Weekly influenza surveillance overview

GERMANY. WCPT COUNTRY PROFILE December 2018

Smokefree Policies in Europe: Are we there yet?

Inequality in injury risks

Report of the 27th Meeting of the European Regional Certification Commission for Poliomyelitis Eradication

Reflecting on ten years of progress in the fight against AIDS, TB and malaria

Influenza Surveillance Country, Territory and Area Profiles 2017

A report on the epidemiology of selected vaccine-preventable diseases in the European Region

Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis?

Table 9.1 Summary information for stomach cancer in Ireland,

Development of Palliative Care services in different countries

EUDY CHILDREN CAMP 2017 FIRST ANNONUCEMENT

SEVENTH MEETING OF THE EUROPEAN REGIONAL VERIFICATION COMMISSION FOR MEASLES AND RUBELLA ELIMINATION (RVC) June 2018 Paris, France

Vaccinations pre- and posttransplant. Burkhard Tönshoff, MD, PhD University Children s Hospital Heidelberg, Germany

European Association of Dental Public Health Prevention of Oral Cancer

Drug Prices Report Opioids Retail and wholesale prices * and purity levels,by drug, region and country or territory (prices expressed in US$ )

Better Health for All in Latvia

Report of the 26th Meeting of the European Regional Certification Commission for Poliomyelitis Eradication

11 Melanoma of the skin

Table 7.1 Summary information for lung cancer in Ireland,

REPORT OF THE 31ST MEETING OF THE EUROPEAN REGIONAL CERTIFICATION COMMISSION FOR POLIOMYELITIS ERADICATION (RCC)

Access to treatment and disease burden

Overall survival: 1 st line therapy

Prevention of Oral Cancer Special Interest Working Group

Department of Biological Standardisation OMCL Network & Healthcare (DBO)

Summary. Week 11/2017 (13 19 March 2017) Season overview

Table 6.1 Summary information for colorectal cancer in Ireland,

Tenth meeting of the European Technical Advisory Group of Experts on Immunization: Outcomes and recommendations

Cardiovascular disease in Europe: epidemiological update 2016

Real Life, Real PD Survey

The Current Status of Cardiac Electrophysiology in ESC Member Countries J. Brugada, P. Vardas, C. Wolpert

The State of Measles and Rubella in the WHO European Region

HPAI H5(N8) in Member States in poultry, captive and wild birds

Cross Border Genetic Testing for Rare Diseases

State of Health In EU: Community Pharmacy Contribution

The challenge of obesity in the WHO European Region

Current Situation on Avian Influenza and the pandemic threat

PRESS RELEASE ISSUED BY THE STATE UNIVERSITY OF NEW YORK AT ALBANY

CALL FOR A EUROPEAN ACTION PLAN FOR MEDICAL IMAGING TO IMPROVE QUALITY OF CARE AND PATIENT SAFETY

Recommended composition of influenza virus vaccines for use in the 2009 southern hemisphere influenza season

Overview of drug-induced deaths in Europe - What does the data tell us?

Monthly measles and rubella monitoring report

REVIEW OF THE ANALYSIS RELATED TO RABIES DIAGNOSIS AND FOLLOW-UP OF ORAL VACCINATION PERFORMED IN NRLS IN 2015

The EHRA White Book 2009 The Current Status of Cardiac Electrophysiology in ESC Member Countries J. Brugada, P. Vardas, C. Wolpert

Budapest, Hungary, September 2017 xx July xxx. Progress reports

National Institute on Alcohol Abuse and Alcoholism. Environmental Approaches

Seventh GF-TADs for Europe Steering Committee meeting (RSC7)

SVERIGES DÖVAS UNGDOMSFÖRBUND (SDUF), SWEDISH YNAD

Information about activities in the region of possible relevance for the regional strategic plan. GF-TADs for Europe

Undetectable = Untransmittable. Mariah Wilberg Communications Specialist

Guidance for Travelers on Temporary Work Assignment Abroad

European Collaboration on Dementia. Luxembourg, 13 December 2006

Positioning health equity and the social determinants of health on the regional development agenda Investment for health and development in Slovenia

Weekly Influenza Surveillance Report. Week 11

Transcription:

RECOMMENDATIONS ON INFLUENZA VACCINATION DURING THE 2018 2019 WINTER SEASON October 2018

Address requests about publications of the WHO Regional Office for Europe to: Publications WHO Regional Office for Europe Marmorvej 51 DK 2100 Copenhagen Ø, Denmark Alternatively, complete an online request form for documentation, health information, or for permission to quote or translate, on the Regional Office website (http://www.euro.who.int/pubrequest). World Health Organization 2018 All rights reserved. The Regional Office for Europe of the World Health Organization welcomes requests for permission to reproduce or translate its publications, in part or in full. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. The views expressed by authors, editors, or expert groups do not necessarily represent the decisions or the stated policy of the World Health Organization.

WHO Regional Office for Europe recommendations on influenza vaccination during the 2018 2019 season Influenza is an infectious disease that spreads mainly from person to person by droplets through coughing, sneezing or talking when people are in close contact. Influenza symptoms begin suddenly and can last from a few days to up to 2 weeks. Common symptoms include fever, cough, body aches and headache. While influenza infection is usually mild and uncomplicated, it may occasionally cause severe disease, particularly among the elderly, pregnant women, young children, and persons with underlying medical conditions. Seasonal influenza vaccination is safe and the most effective means of preventing infection and severe outcomes caused by influenza viruses. RECOMMENDED TARGET GROUPS FOR INFLUENZA VACCINATION Vaccination can benefit persons of all ages but is especially important for people at higher risk of serious influenza complications. Specific population groups may be targeted for vaccination depending on the objectives of the national vaccination programme, documented vaccine effectiveness, access to vaccine, and the ability to implement vaccination campaigns in the target groups. The priority groups for influenza immunization are drawn from the 2012 WHO position paper on influenza vaccines 1 and include: pregnant women; individuals with chronic heart or lung diseases, metabolic or renal disease, chronic liver disease, chronic neurological conditions or immunodeficiencies; elderly persons over a nationally defined age limit, irrespective of other risk factors; residents of long-term care facilities for older persons and the disabled; children aged 6 59 months; health care workers including those who work in facilities that care for the elderly or persons with disabilities. Additional information Information sheets on reaction rates of seasonal influenza vaccines (available in English and Russian) http://www.who.int/vaccine_safety/initiative/tools/vaccinfosheets/en/ COMPOSITION OF INFLUENZA VACCINES FOR 2018 2019 Due to the influenza virus continuous genetic and antigenic changes, WHO updates its recommendations for the composition of the vaccine twice a year for the northern and southern hemisphere, respectively. The viruses included in the vaccine are those predicted to be the most common in the forthcoming season. Because the composition of the vaccine is updated regularly to produce the best protection, vaccination against influenza is recommended every year before the season begins. As it takes approximately 6 8 months to produce influenza vaccines, 1 Seasonal influenza vaccine, Weekly Epidemiological Record: 2012 (21); 87, 201 16 (www.who.int/wer/2012/wer8721.pdf) 1

recommendations for the vaccine composition for the northern hemisphere are published by WHO in February every year. During the upcoming 2018 2019 influenza season, WHO recommends that trivalent seasonal influenza vaccines for use in the northern hemisphere contain 2 : an A/Michigan/45/2015 (H1N1)pdm09-like virus; an A/Singapore/INFIMH-16-0019/2016 (H3N2)-like virus; and a B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage) It is recommended that quadrivalent vaccines include a B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage) in addition to the three viruses above. This year s northern hemisphere vaccine composition represents two changes compared with the vaccine used for the 2017 2018 season with the influenza B/Victoria lineage virus component and the A(H3N2) virus component being updated. The update is as follows: Replacement of the A/Hong Kong/4801/2014 (H3N2)-like virus with an A/Singapore/INFIMH- 16-0019/2016 (H3N2)-like virus. Replacement of the B/Brisbane/60/2008-like virus with a B/Colorado/06/2017-like virus. WHO is continuously monitoring influenza virus circulation globally and will provide updated recommendations as needed. 2 Recommended composition of influenza virus vaccines for use in the 2018 2019 northern hemisphere influenza season; http://www.who.int/influenza/vaccines/virus/recommendations/2018_19_north/en/ 2

The WHO Regional Office for Europe The World Health Organization (WHO) is a specialized agency of the United Nations created in 1948 with the primary responsibility for international health matters and public health. The WHO Regional Office for Europe is one of six regional offices throughout the world, each with its own programme geared to the particular health conditions of the countries it serves. Member States Albania Andorra Armenia Austria Azerbaijan Belarus Belgium Bosnia and Herzegovina Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland France Georgia Germany Greece Hungary Iceland Ireland Israel Italy Kazakhstan Kyrgyzstan Latvia Lithuania Luxembourg Malta Monaco Montenegro Netherlands Norway Poland Portugal Republic of Moldova Romania Russian Federation San Marino Serbia Slovakia Slovenia Spain Sweden Switzerland Tajikistan The former Yugoslav Republic of Macedonia Turkey Turkmenistan Ukraine United Kingdom Uzbekistan World Health Organization Regional Office for Europe UN City, Marmorvej 51, DK-2100 Copenhagen Ø, Denmark Tel: +45 45 33 70 00 Fax: +45 45 33 70 01 Email: eucontact@who.int Website: www.euro.who.int